Since the introduction of the combined radiation and EGFR-inhibition as a standard concept for SCCHN though, targeted therapies such as the EGFR receptor antibody cetuximab have also gained interes. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.